The offering is a clear negative for near-term price action due to ~12.6% immediate dilution and a 5% discount placement. However, the extremely strong clinical data (92% ORR) and the $567M cash infusion that extends runway into 2030 to fund a Phase 3 pivotal trial create a strong bull case medium-term. Traders should expect a gap-down at the open on June 11 (closing date), but watch for buying into weakness if the trial data narrative remains intact. The 60-day insider lock-up limits secondary selling pressure.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 11 $29.82entry
- T+1 · 5mo ago +3.76%α +3.21% · $30.94
- T+5 · 5mo ago +8.28%α +7.85% · $32.29
- T+20 · 4mo ago +2.35%α +0.46% · $30.52
- T+60 · 2mo ago −23.88%α −27.70% · $22.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tango Therapeutics is raising approximately $566.5 million in net proceeds through a public offering of 18,166,667 shares of common stock at $30.00 per share and pre-funded warrants to purchase 1,833,395 shares. The offering priced at a 4.9% discount to the prior closing price of $31.56, resulting in immediate and substantial dilution of $24.10 per share to new investors. The capital raise follows highly positive Phase 1/2 clinical data for its lead candidate vopimetostat in combination with RAS inhibitors, showing a 92% objective response rate in pancreatic cancer, which positioned the company to advance into Phase 3 development. The proceeds are expected to fund operations into 2030 including a pivotal trial and potential commercialization. The large dilutive offering paired with very strong clinical data creates a mixed signal for the stock.
Key Facts
- Offering of 18,166,667 shares of common stock at $30.00 per share
- Pre-funded warrants to purchase 1,833,395 shares at $29.999 per warrant
- Net proceeds of approximately $566.5 million ($651.6 million if underwriters exercise full option for 3,000,009 additional shares)
- Offering price at a ~4.9% discount to last sale of $31.56 on June 9, 2026
- Immediate dilution of $24.10 per share to new investors based on net tangible book value
- As adjusted net tangible book value of $5.90 per share post-offering vs offering price of $30.00
- Proceeds expected to fund operations into 2030, including pivotal Phase 3 trial for vopimetostat
- Follows June 8, 2026 data showing 92% ORR in PDAC with daraxonrasib combination and plans to initiate Phase 3
- Underwriters granted 30-day option for additional shares up to 15% of offering
- Insiders and company subject to 60-day lock-up
- ATM facility for up to $35.6 million remains available after lock-up expiration
Financial Impact
~$567M gross capital raise at ~5% discount to market, resulting in ~12.6% dilution to existing shareholders (18.2M new shares vs 144.2M pre-offering outstanding); underwriter fees of ~$33M
Risk Factors
- Immediate dilution of ~12.6% to existing shareholders
- Offering priced at discount to last closing price may pressure stock near-term
- Clinical-stage biotech with no approved products or current revenue
- No clinical trial supply agreement in place yet for Phase 3 daraxonrasib combination
- Dependence on third-party collaborators for drug supply (Revolution Medicines, Erasca)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-266074 |
| Document: d151329dexfilingfees.htm | 0001193125-26-266074 |
| Document: 0001193125-26-266074-index-headers.html | 0001193125-26-266074 |
| Document: 0001193125-26-266074-index.html | 0001193125-26-266074 |
| Document: 0001193125-26-266074.txt | 0001193125-26-266074 |
Track record
27 reports on TNGX
3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
- Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers